Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization - Clinical Core

点击翻译按钮获取中文摘要

The Clinical Core will continue to provide the leadership and expertise in clinical infectious diseases and human subjects research to support the HIPC3 and our collaboration’s three scientific projects focused on comprehensive immune analysis of malaria, HIV-1 and SARS-CoV-2 prevention and infection. Based within the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Research Center, the Clinical Core will establish, conduct and oversee clinical cohort observational studies and human immunology studies nested within clinical vaccine trials in order to obtain longitudinal specimens for deep immune profiling investigations. To accomplish our goals, we propose to provide the clinical infrastructure, leadership, expertise and to conduct human subjects research in infectious diseases on behalf of our HIPC3 Collaboration through observational studies and sub-studies nested within existing and future clinical trials. We also aim to design, develop, implement and maintain well-curated clinical cohorts and vaccine trial sub-studies to acquire specimens for immune profiling studies relevant to malaria, HIV-1 and SARS-CoV-2, either during or after infection, or before and after immunization.